1. Clinical benefit of high dose IL-2 (HD IL-2) therapy: evidence for improved overall survival in patients with stable disease Hughes, Tasha; Iodice, Gail M.; Basu, Sanjib; Bines, Steven; Kaufman, Howard 2013 Presentations (Communicative Events) Cancer--ImmunotherapyMelanoma--TreatmentRenal cell carcinomaInterleukin-2ImmunotherapyOncologyMedicineImmunology
2. Immunotargeting of tumor vasculature: preclinical development of novel antibody-based imaging and therapy against TEM1/CD248 Li, Chunsheng; Wang, Junying; Hu, Jia; Chacko, Ann; Zhao, Aizhi; Divgi, Chaitanya R.; Muzykantov, Vladimir; Coukos, George 2013 Presentations (Communicative Events) Tumors--Blood-vesselsCancer--TreatmentOvaries--CancerOvaries--Cancer--TreatmentImmunoglobulins--Therapeutic useCancer--ImagingCancer--ImmunotherapyImmunologyOncologyMedicineDiagnostic imaging
3. The role of surgery following incomplete response to high-dose IL-2 (HD IL-2) Hughes, Tasha; Iodice, Gail M.; Basu, Sanjib; Bines, Steven; Kaufman, Howard 2013 Presentations (Communicative Events) Excision (Surgery)Metastasis--SurgeryMetastasisMetastasis--TreatmentCancer--SurgeryCancer--ImmunotherapyInterleukin-2OncologyMedicineSurgeryImmunology
4. Tumor-associated T cell receptor repertoires in low- and high-grade gliomas Sims, Jennifer S.; Grinshpun, Boris; Amendolara, Benjamin; Shen, Yufeng; Canoll, Peter D.; Sims, Peter A.; Bruce, Jeffrey N. 2013 Presentations (Communicative Events) AstrocytomasGliomasT cells--ReceptorsExcision (Surgery)Cancer--SurgeryGlioblastoma multiformeOncologySurgeryMedicine